Welcome to the European Society for Medical Oncology (ESMO), the leading European professional organization representing medical oncologists. more about ESMO ...
ESMO FAMILY SITES
ESMO NEWS
- 20.07.10 - José Carreras will perform at the ESMO Foundation Benefit Concert, 10 October 2010, during the 35th ESMO Congress
JOSÉ CARRERAS RETURNS TO LA SCALA
AFTER AN ABSENCE OF 14 YEARS
“CANCER HAS TAUGHT ME TO LISTEN...
- 14.07.10 - Chronic Disease Alliance: A unified approach
In June 2010, ESMO, as a member of the ‘European’ Chronic Disease Alliance, presented a policy...
- 06.07.10 - Annals of Oncology climbs the rankings
The Annals of Oncology Impact Factor has increased by 14% to reach 5.647 in the recently released...
- 28.06.10 - ESMO Clinical Practice Guidelines offering the best standards of cancer care with improved methodology
Formerly known as the ESMO Clinical Recommendations, the ESMO Clinical Practice Guidelines (CPG)...
- 28.06.10 - “How to use EGFR mutations to optimize treatment selection in NSCLC”, by Dr Federico Cappuzzo is the latest ESMO E-Learning Module
The presentation provides an excellent overview on retrospective and prospective studies of...
[more...]
ONCOLOGY NEWS
- 19.07.10 - Imaging of ovarian cancer and peritoneal metastases
Current and emerging techniques
- 13.07.10 - Human papillomavirus and survival of patients with oropharyngeal cancer
New study found that tumor HPV status is a strong and independent prognostic factor for survival...
- 12.07.10 - Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy
Co-targeting IGF1R and insulin receptor may result in unacceptable toxicity but it might be...
- 09.07.10 - Updated safety data from a randomized Phase 2 trial of Hedgehog pathway inhibitor GDC-0449 vs. placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer
Novelties from the ESMO 12th World Congress on Gastrointestinal Cancer (30 June-3 July 2010,...
- 06.07.10 - Allogenic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation
Results of a retrospective study based on the time of HLA typing and donor availability
[more...]
ESMO Practice Tools
myESMO Network
Virtual Meetings
ESMO Examination